Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ: BMRN )

68.81 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7
Open 68.81
Bid (Size) 68.08 (7)
Ask (Size) 70.92 (1)
Prev. Close 68.81
Today's Range 68.81 - 68.81
52wk Range 60.63 - 94.85
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know. 
Via StockStory
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know. 
Via StockStory

Performance

YTD
+3.49%
+3.49%
1 Month
+11.34%
+11.34%
3 Month
+5.18%
+5.18%
6 Month
-23.82%
-23.82%
1 Year
-24.12%
-24.12%

More News

Read More
What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings
Via StockStory
Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today
Via The Motley Fool
Demystifying Biomarin Pharmaceutical: Insights From 8 Analyst Reviews
Via Benzinga
Earnings Scheduled For February 19, 2025
Via Benzinga
NASDAQ:BMRN, a growth stock which is not overvalued.
Via Chartmill
The Latest Analyst Ratings For Biomarin Pharmaceutical
Via Benzinga
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
Via StockStory
Why Is BioMarin Stock Trading Higher On Thursday?
Via Benzinga
BioMarin: EPS Surges Past Expectations
Via The Motley Fool
BioMarin Pharmaceutical (NASDAQ:BMRN) Reports Bullish Q4, Stock Soars
Via StockStory
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings
Via StockStory
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
Via Chartmill
NASDAQ:BMRN is an undervalued gem with solid fundamentals.
Via Chartmill
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Via Benzinga
NASDAQ:BMRN is showing decent growth, but is still valued reasonably.
Via Chartmill
Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators
Via Benzinga
Topics ETFs
10 Magnificent Stocks That Can Make You Richer in 2025
Via The Motley Fool
NASDAQ:BMRN stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
Via Chartmill
When you look at NASDAQ:BMRN, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Can BioMarin Stock Live Up to Wall Street’s High Expectations?
Via MarketBeat
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.